Alkermes CEO Pops stays focused on 5461 filing plans; Shkreli gets booed at Harvard
• Alkermes $ALKS is moving ahead with plans to file a new depression drug, ALKS-5461, later in the year. “This is a fast-track designated medicine,” CEO Richard Pops told analysts in Wednesday’s quarterly call. “As we’ve done throughout the development process, earlier this week we met with FDA for a Type C scientific exchange to share with them the data from FORWARD-5. The meeting with FDA was productive, and we are on track with the plan submission of the NDA in the second half of the year.” And he is pushing ahead with a careful eye on ALKS-3831, “which is coming into focus as the pivotal program matures.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.